PolyPeptide Group AG
PPGN
Company Profile
Business description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
Contact
Neuhofstrasse 24
Baar
Zug6340
CHET: +41 435020580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,395
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.20 | 11.20 | 0.13% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,412.90 | 64.99 | 0.25% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 63,172.02 | 429.45 | 0.68% |
| NZX 50 Index | 13,053.31 | 27.02 | -0.21% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,635.60 | 4.60 | 0.05% |
| SSE Composite Index | 4,218.22 | 3.73 | 0.09% |